Jennifer Pietenpol Archive — Page 1 of 4

Authors on the study included, from left, Jennifer Pietenpol, PhD, Melinda Sanders, MD, Brian Lehmann, PhD, Vandana Abramson, MD, and Yu Shyr, PhD. (photo by Donn Jones)
December 15, 2023

Clinical trial shows efficacy for atezolizumab combined with carboplatin

The new combination significantly improved progression-free and overall survival of patients with metastatic triple-negative breast cancer.

Professional head-and-shoulders portrait of Jennifer Pietenpol, PhD, wearing a dark blazer against a mottled brown background.
March 22, 2022

VUMC’s Pietenpol, Shyr named AACR Fellows

Vanderbilt’s Jennifer Pietenpol, PhD, and Yu Shyr, PhD, have been inducted as fellows of the American Association for Cancer Research Academy.

Professional head-and-shoulders portrait of Jennifer Pietenpol, PhD, wearing a dark blazer against a mottled brown background.
February 10, 2022

Pietenpol named chief scientific and strategy officer

Jennifer Pietenpol, PhD, director of the Vanderbilt-Ingram Cancer Center (VICC), Benjamin F. Byrd Jr. Professor of Oncology and Executive Vice President for Research for Vanderbilt University Medical Center, is stepping down on June 30 from her long-held role as the Cancer Center’s director to focus on a combined leadership role for VUMC as chief scientific and strategy officer (CSSO).

November 18, 2021

‘Multi-omics’ reveals treatment option for breast cancer subtype

The team studying tumor suppressor protein p53 includes, from left, Jennifer Pietenpol, PhD, and Lindsay Redman-Rivera.
September 2, 2021

Discovery offers insight for development of cancer therapies targeting mutant p53

Vanderbilt researchers have discovered that aneuploidy (an abnormal number of chromosomes) drives malignant phenotypes in cells expressing mutant p53, a tumor suppressor protein that is mutated in more than half of all human cancers.

Three rows of tissue microscopy panels showing stained tissue sections alongside separate blue, green, and red fluorescence channels and merged overlays with outlined regions.
August 19, 2021

Expression atlas for cell regulators

Vanderbilt researchers report a comprehensive tissue-specific atlas of protein and mRNA expression for p63 and p73, members of the p53 family signaling network that is the most frequent target of mutations in human cancers.